Therapy Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | STX-478 |
| Synonyms | |
| Therapy Description |
STX-478 inhibits PIK3CA H1047 mutations, potentially resulting in decreased tumor cell proliferation and reduced tumor growth (Cancer Res 2023;83(5 Suppl):Abstract nr P4-07-04). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| STX-478 | STX 478|STX478 | PIK3CA inhibitor 24 | STX-478 inhibits PIK3CA H1047 mutations, potentially resulting in decreased tumor cell proliferation and reduced tumor growth (Cancer Res 2023;83(5 Suppl):Abstract nr P4-07-04). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| PIK3CA H1047R | Her2-receptor negative breast cancer | sensitive | STX-478 | Preclinical - Pdx & cell culture | Actionable | In a preclinical study, STX-478 inhibited viability in an ESR1-positive, ERBB2 (HER2)-negative breast cancer cell line harboring PIK3CA H1047R in culture and inhibited tumor growth and induced tumor regression with high-dose STX-478 in a cell line xenograft model and inhibited tumor growth in a patient-derived xenograft (PDX) model (PMID: 37623743). | 37623743 |
| PIK3CA H1047L | colon cancer | sensitive | STX-478 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, STX-478 inhibited viability in a colon cancer cell line harboring PIK3CA H1047L in culture, and inhibited tumor growth and induced tumor regression in a cell line xenograft model (PMID: 37623743). | 37623743 |
| PIK3CA E542K PIK3CA H1065L | breast cancer | sensitive | STX-478 | Preclinical - Pdx | Actionable | In a preclinical study, STX-478 inhibited tumor growth of a breast cancer patient-derived xenograft (PDX) model harboring PIK3CA E542K and H1065L (PMID: 37623743). | 37623743 |
| PIK3CA D350N PIK3CA H1047R | Advanced Solid Tumor | sensitive | STX-478 | Preclinical - Cell culture | Actionable | In a preclinical study, STX-478 inhibited viability of a cell line harboring PIK3CA H1047R and D350N in culture (PMID: 37623743). | 37623743 |
| PIK3CA H1047R | Her2-receptor positive breast cancer | sensitive | STX-478 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, STX-478 inhibited viability in a hormone receptor-negative, ERBB2 (HER2)-positive breast cancer cell line harboring PIK3CA H1047R in culture, and inhibited tumor growth in a cell line xenograft model (PMID: 37623743). | 37623743 |
| PIK3CA K111R PIK3CA H1047R | lung carcinoma | sensitive | STX-478 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, STX-478 inhibited viability in a lung carcinoma cell line harboring PIK3CA H1047R and K111R in culture, and inhibited tumor growth in a cell line xenograft model (PMID: 37623743). | 37623743 |
| PIK3CA E542K | Her2-receptor positive breast cancer | sensitive | STX-478 | Preclinical - Pdx | Actionable | In a preclinical study, STX-478 inhibited tumor growth of a ERBB2 (HER2)-positive breast cancer patient-derived xenograft (PDX) model harboring PIK3CA E542K (PMID: 37623743). | 37623743 |
| PIK3CA E545K | head and neck squamous cell carcinoma | sensitive | STX-478 | Preclinical - Pdx | Actionable | In a preclinical study, STX-478 inhibited tumor growth of a head and neck squamous cell cancer patient-derived xenograft (PDX) model harboring PIK3CA E545K (PMID: 37623743). | 37623743 |
| PIK3CA P539R PIK3CA H1047R | Advanced Solid Tumor | sensitive | STX-478 | Preclinical - Cell culture | Actionable | In a preclinical study, STX-478 inhibited viability of a cell line harboring PIK3CA H1047R and P539R in culture (PMID: 37623743). | 37623743 |
| PIK3CA H1047R | head and neck squamous cell carcinoma | sensitive | STX-478 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, STX-478 inhibited viability in head and neck squamous cell cancer cell lines harboring PIK3CA H1047R in culture, and inhibited tumor growth and induced tumor regression in a cell line xenograft model (PMID: 37623743). | 37623743 |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05768139 | Phase Ib/II | Fulvestrant + STX-478 STX-478 | First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors | Recruiting | USA | ITA | FRA | ESP | 0 |
CKB BOOST